Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence-based summary of optimal home self-management for elderly ostomy patients.

Frontiers in medicine·2026
Same author

Toxic mechanisms of environmentally relevant titanium dioxide nanoparticles to Chlorella under coupled multi-environmental factors.

Journal of environmental management·2026
Same author

Programmable antibody-based chimeric entry receptors for sarbecoviruses.

Communications biology·2026
Same author

Prediction models for postpartum post-traumatic stress disorder: a systematic review and meta-analysis.

BMC psychiatry·2026
Same author

A foundation generative model for breast ultrasound image analysis.

Nature biomedical engineering·2026
Same author

Negative emotional symptoms and e-Health literacy among Chinese college students: a latent profile analysis.

Frontiers in psychology·2026

Related Experiment Video

Updated: Jun 16, 2026

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation
19:23

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation

Published on: January 16, 2019

9.3K

A programmable protease-based protein secretion platform for therapeutic applications.

Xinyi Wang1, Liping Kang1, Deqiang Kong1

  • 1Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.

Nature Chemical Biology
|October 23, 2023
PubMed
Summary
This summary is machine-generated.

This study introduces a protease-based rapid protein secretion system (PASS) for cell therapies. PASS enables rapid, on-demand secretion of therapeutic proteins, advancing precision medicine.

More Related Videos

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells
07:09

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells

Published on: July 31, 2012

21.2K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.3K

Related Experiment Videos

Last Updated: Jun 16, 2026

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation
19:23

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation

Published on: January 16, 2019

9.3K
A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells
07:09

A Convenient and General Expression Platform for the Production of Secreted Proteins from Human Cells

Published on: July 31, 2012

21.2K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.3K

Area of Science:

  • Biomedical Science
  • Cell Therapy Engineering
  • Molecular Biology

Background:

  • Current cell therapies rely on transcription/translation for therapeutic output.
  • Existing genetic control systems lack rapid protein secretion capabilities.
  • Engineered cells require precise and timely delivery of therapeutic proteins.

Purpose of the Study:

  • To develop a novel protease-based rapid protein secretion system (PASS) for cell-based therapies.
  • To demonstrate the flexibility and efficacy of PASS variants in different therapeutic contexts.
  • To enable rapid, inducible secretion of pretranslated proteins from the endoplasmic reticulum.

Main Methods:

  • Development of three PASS variants: chemPASS, antigenPASS, and optoPASS.
  • Utilizing an ER-retrieval signal to retain pretranslated proteins.
  • Employing inducible proteases for controlled protein release.
  • In vivo validation in mouse models for diabetes, cancer, and pain.

Main Results:

  • chemPASS demonstrated rapid insulin secretion to reverse hyperglycemia in diabetic mice.
  • antigenPASS induced targeted tumor cell apoptosis via granzyme B and perforin secretion.
  • optoPASS enabled light-induced therapeutic peptide secretion within minutes for various conditions.
  • PASS facilitated rapid therapeutic protein delivery across diverse disease models.

Conclusions:

  • The protease-based rapid protein secretion system (PASS) offers a flexible platform for cell-based therapies.
  • PASS enables rapid, controlled delivery of therapeutic proteins, enhancing precision medicine.
  • This technology has the potential to accelerate the development and adoption of advanced cell therapies.